Press Releases
  Date Title View
ROCKVILLE, Md., June 21, 2017 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN), a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced that the U.S. Food and Drug Administration (FDA) has approved MydayisTM (mixed salts of a ...
Posted: Jun 21, 2017
ROCKVILLE, Md., June 01, 2017 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN), a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases, today announced that the Company's management will present an overview and update for the Company, and host inve...
Posted: Jun 1, 2017
Net product sales were $56.4 million, a 31% increase over 2016.Operating income was $16.8 million, a 161% increase over 2016.Diluted earnings per share were $0.19, increasing by 138% over 2016.Early prescription data for Trokendi XR show a strong upward trend following launch in migraine prophylaxis in adults and adolescents. ROCKVILLE, Md., May ...
Posted: May 9, 2017
ROCKVILLE, Md., April 26, 2017 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN), a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced that the Company expects to report the financial results for the first quarter of 2017 af...
Posted: Apr 26, 2017
ROCKVILLE, Md., April 05, 2017 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq:SUPN), a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases, today announced that the Food and Drug Administration (FDA) has granted final approval to the Company's Supplem...
Posted: Apr 5, 2017
ROCKVILLE, Md., March 07, 2017 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq:SUPN), a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases, announced that it has entered into a binding term sheet with Actavis Laboratories, FL, Inc. et al. (collectivel...
Posted: Mar 7, 2017
ROCKVILLE, Md., March 06, 2017 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq:SUPN), a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases, announced that it has entered into a settlement agreement with Zydus Pharmaceutical (USA), Inc. and Cadila Heal...
Posted: Mar 6, 2017
Fourth quarter 2016 net product sales were $61.1 million, a 43% increase over 2015.Fourth quarter operating income was $16.3 million, a 107% increase over 2015.Fourth quarter diluted earnings per share were $0.26, an 86% increase over 2015.Full year 2016 net product sales were $210.1 million, a 46% increase over 2015.Full year 2016 operating income...
Posted: Feb 28, 2017
ROCKVILLE, Md., Feb. 27, 2017 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN), a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases, today announced that the Company's management will present an overview and update of the company and host invest...
Posted: Feb 27, 2017
ROCKVILLE, Md., Feb. 13, 2017 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN), a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced that the Company expects to report financial results for the fourth quarter and full year ...
Posted: Feb 13, 2017
1
...
NextLast
= add release to Briefcase